- Olokizumab (OKZ) is a promising monoclonal antibody for treating rheumatoid arthritis, showing significant efficacy in recent clinical trials and this meta-analysis evaluates its effectiveness and safety in patients not responding well to standard treatments.
- The review included five trials with 2,761 patients, demonstrating that various dosages of OKZ led to statistically significant improvements in disease activity scales (ACR 20, 50, and 70) compared to placebo, with notable improvements across all treatment groups.
- While the safety profile of OKZ was favorable, showing comparable mortality rates to placebo, the authors recommend larger and longer-term studies to further validate these positive results.